| The WT FLT3 allele seemingly functions as a tumor suppressor, attenuating the function of the FLT3/ITD allele in leukemia harboring FLT3/ITD mutations. | leukemia, |
| excessive Flt3 expression has growth-suppressive properties in several human cancer cell lines | None |
| BH3-only protein Bim more critical than Puma in tyrosine kinase inhibitor-induced apoptosis of human leukemic cells and transduced hematopoietic progenitors carrying oncogenic FLT3. | leukemia, |
| Detection of FLT3 oncogene mutations in acute myeloid leukemia using conformation sensitive gel electrophoresis. | leukemia, |
| A robust error model for iTRAQ quantification reveals divergent signaling between oncogenic FLT3 mutants in acute myeloid leukemia. | leukemia, |
| oncogenic FLT3 regulates proteins involving diverse cellular processes and affects multiple signaling pathways in human leukemia | leukemia, |
| Grb10 binds to both normal and oncogenic FLT3 and induces PI3K-Akt and STAT5 signaling pathways resulting in an enhanced proliferation, survival and colony formation of hematopoietic cells. | colorectal, |
| our data suggest intracellular protein transport as a potential target for FLT3-ITD driven leukemias, with KDELR1 emerging as a positive modulator of oncogenic FLT3-ITD activity | leukemia, |
| Features of Ras activation by a mislocalized oncogenic tyrosine kinase: FLT3 ITD signals through K-Ras at the plasma membrane of acute myeloid leukemia cells. | leukemia, |
| IDH2 mutants can cooperate with oncogenic Flt3 or Nras alleles to drive leukemia in mice by impairing the differentiation of cells of the myeloid lineage | leukemia, |
| Independent oncogenic and therapeutic significance of phosphatase PRL-3 in FLT3-ITD-negative acute myeloid leukemia. | leukemia, |
| Identify CDC25A as an early cell cycle transducer of FLT3-ITD oncogenic signaling, and as a promising target to inhibit proliferation and re-induce differentiation of FLT3-ITD acute myeloid leukemia cells. | leukemia, |
| The study revealed that PRMT1 methylates Fms-like receptor tyrosine kinase 3 (FLT3) at arginine (R) residues 972 and 973 (R972/973), and its oncogenic function in MLL - rearranged acute lymphoblastic leukemia cells is FLT3 methylation dependent. | leukemia, |
| Normal and oncogenic FLT3. | None |
| Meis1 programs transcription of FLT3 and cancer stem cell character, using a mechanism that requires interaction with Pbx and a novel function of the Meis1 C-terminus. | None |
| Signal transduction of oncogenic Flt3. | None |
| FLT3 activation induces beta-catenin tyrosine phosphorylation and nuclear localization, suggesting a mechanism for the association of FLT3 activation and beta-catenin oncogeneic signaling in AML. | None |
| We identified two tyrosine residues, Y589 and Y591, in the juxtamembrane domain that are critical for the ligand-dependent activation of FLT3-WT and the transforming potential of oncogenic FLT3 mutants. | None |
| Transformation by oncogenic mutants and ligand-dependent activation of FLT3 wild-type requires the tyrosine residues 589 and 591. | None |
| Oncogenic Flt3 receptors display different specificity and kinetics of autophosphorylation. | None |